These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 29808997

  • 1. Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma.
    Huang KW, Lai YT, Chern GJ, Huang SF, Tsai CL, Sung YC, Chiang CC, Hwang PB, Ho TL, Huang RL, Shiue TY, Chen Y, Wang SK.
    Biomacromolecules; 2018 Jun 11; 19(6):2330-2339. PubMed ID: 29808997
    [Abstract] [Full Text] [Related]

  • 2. Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy.
    Wu JY, Wang ZX, Zhang G, Lu X, Qiang GH, Hu W, Ji AL, Wu JH, Jiang CP.
    Int J Nanomedicine; 2018 Jun 11; 13():1265-1280. PubMed ID: 29551896
    [Abstract] [Full Text] [Related]

  • 3. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J, Farzan M.
    World J Gastroenterol; 2015 Nov 14; 21(42):12022-41. PubMed ID: 26576089
    [Abstract] [Full Text] [Related]

  • 4. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.
    Pranatharthiharan S, Patel MD, Malshe VC, Pujari V, Gorakshakar A, Madkaikar M, Ghosh K, Devarajan PV.
    Drug Deliv; 2017 Nov 14; 24(1):20-29. PubMed ID: 28155331
    [Abstract] [Full Text] [Related]

  • 5. Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma.
    Shi B, Abrams M, Sepp-Lorenzino L.
    J Histochem Cytochem; 2013 Dec 14; 61(12):901-9. PubMed ID: 23979840
    [Abstract] [Full Text] [Related]

  • 6. Lipid-modified cell-penetrating peptide-based self-assembly micelles for co-delivery of narciclasine and siULK1 in hepatocellular carcinoma therapy.
    Wang X, Wu F, Li G, Zhang N, Song X, Zheng Y, Gong C, Han B, He G.
    Acta Biomater; 2018 Jul 01; 74():414-429. PubMed ID: 29787814
    [Abstract] [Full Text] [Related]

  • 7. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy.
    Han L, Tang C, Yin C.
    Biomaterials; 2014 May 01; 35(15):4589-600. PubMed ID: 24613049
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A supramolecular nanoparticle system based on β-cyclodextrin-conjugated poly-l-lysine and hyaluronic acid for co-delivery of gene and chemotherapy agent targeting hepatocellular carcinoma.
    Xiong Q, Cui M, Bai Y, Liu Y, Liu D, Song T.
    Colloids Surf B Biointerfaces; 2017 Jul 01; 155():93-103. PubMed ID: 28411478
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Superparamagnetic iron oxide nanoparticles modified with polyethylenimine and galactose for siRNA targeted delivery in hepatocellular carcinoma therapy.
    Yang Z, Duan J, Wang J, Liu Q, Shang R, Yang X, Lu P, Xia C, Wang L, Dou K.
    Int J Nanomedicine; 2018 Jul 01; 13():1851-1865. PubMed ID: 29618926
    [Abstract] [Full Text] [Related]

  • 17. Asialoglycoprotein receptor-magnetic dual targeting nanoparticles for delivery of RASSF1A to hepatocellular carcinoma.
    Xue WJ, Feng Y, Wang F, Guo YB, Li P, Wang L, Liu YF, Wang ZW, Yang YM, Mao QS.
    Sci Rep; 2016 Feb 26; 6():22149. PubMed ID: 26915683
    [Abstract] [Full Text] [Related]

  • 18. Galactose-modified cationic liposomes as a liver-targeting delivery system for small interfering RNA.
    Sonoke S, Ueda T, Fujiwara K, Kuwabara K, Yano J.
    Biol Pharm Bull; 2011 Feb 26; 34(8):1338-42. PubMed ID: 21804229
    [Abstract] [Full Text] [Related]

  • 19. Biodistribution and biocompatibility of glycyrrhetinic acid and galactose-modified chitosan nanoparticles as a novel targeting vehicle for hepatocellular carcinoma.
    Li M, Wang Y, Jiang S, Gao Y, Zhang W, Hu S, Cheng X, Zhang C, Sun P, Ke W, Wang G, Song Z, Zhang Y, Zheng QC.
    Nanomedicine (Lond); 2020 Jan 26; 15(2):145-161. PubMed ID: 31782335
    [Abstract] [Full Text] [Related]

  • 20. In vitro and in vivo evaluation of self-assembled chitosan nanoparticles selectively overcoming hepatocellular carcinoma via asialoglycoprotein receptor.
    Sun R, Fang L, Lv X, Fang J, Wang Y, Chen D, Wang L, Chen J, Qi Y, Tang Z, Zhang J, Tian Y.
    Drug Deliv; 2021 Dec 26; 28(1):2071-2084. PubMed ID: 34595970
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.